Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Phase 2 in Obesity
NCT02453711Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in obesity (9 arms), sponsored by Novo Nordisk. Primary endpoint: Relative Change in Body Weight at 52 weeks. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02453711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453711.